Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...
Automated Portal-Enabled Elicitation of Health-Related Patient Values in Solid Tumor Oncology: Feasibility and Patient Characteristics Associated With Patient Response The following represents ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor ...
A new study designs drugs that bind to intrinsically disordered proteins that are extremely difficult to target due to their flexible nature.
Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results